Organon (OGN) Cash from Discontinued Operations (2020 - 2021)

Organon (OGN) recorded quarterly Cash from Discontinued Operations of 356000000.0 in Q3 2021, up 2077.78% quarter-over-quarter from 18000000.0 in Q2 2021, and up 173.85% on a YoY basis from 130000000.0 in Q3 2020.

Organon (OGN) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Organon's Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 356000000.0 for Q3 2021.

  • In Q3 2021, Cash from Discontinued Operations rose 173.85% year-over-year to 356000000.0; the TTM figure through Jun 2022 stood at 356000000.0 (up 216.72% YoY), while the FY2021 annual figure was 298000000.0, up 215.5% from the prior year.
  • Cash from Discontinued Operations was 356000000.0 for Q3 2021 at Organon, up from 18000000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 356000000.0 in Q3 2021 to a low of 377000000.0 in Q4 2020.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Gsk 93,026,132.38 Bn 93,026,127.42 Bn 7.76 Bn 1.54 Bn
2 Eli Lilly 1,022.62 Bn 1,017.34 Bn 16.22 Bn -
3 Johnson & Johnson 570.65 Bn 548.59 Bn 15.96 Bn -
4 AbbVie 398.73 Bn 389.38 Bn 10.78 Bn -
5 Merck 295.53 Bn 289.88 Bn 12.09 Bn -
6 Amgen 186.30 Bn 174.26 Bn 5.87 Bn -
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -
8 Pfizer 146.09 Bn 133.32 Bn -1.21 Bn -
9 Bristol Myers Squibb 114.98 Bn 104.53 Bn 8.07 Bn -
10 Organon 3.49 Bn 2.37 Bn 783.00 Mn -

Historic Data

Download Data
DateValue
Sep 30, 2021 356.00 Mn
Sep 30, 2021 356.00 Mn
Jun 30, 2021 -18.00 Mn
Jun 30, 2021 -18.00 Mn
Mar 31, 2021 -40.00 Mn
Mar 31, 2021 -40.00 Mn
Dec 31, 2020 -377.00 Mn
Dec 31, 2020 -377.00 Mn
Sep 30, 2020 130.00 Mn
Sep 30, 2020 130.00 Mn
Jun 30, 2020 70.00 Mn
Jun 30, 2020 70.00 Mn
Mar 31, 2020 -81.00 Mn
Mar 31, 2020 -81.00 Mn